NCT06852170 Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
| NCT ID | NCT06852170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chestnut Health Systems |
| Condition | Substance Abuse |
| Study Type | INTERVENTIONAL |
| Enrollment | 341 participants |
| Start Date | 2025-02-06 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 341 participants in total. It began in 2025-02-06 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Oregon's decision makers (e.g., community service providers, public health, justice, advocacy groups, payers) are calling for comprehensive, current, and trusted data to inform how they allocate resources to improve substance use services and mitigate the growing opioid and methamphetamine epidemics in their state. Consistent with the HEAL Data2Action call for Innovation projects that drive action with data in real-world settings, this study will refine and test the impact of a novel implementation strategy to engage cross- sector decision makers and make data that they identify as relevant to their decisions available to them in easy- to-use products. The proposed study aims to not only address critical knowledge gaps regarding how and when data can inform impactful, transparent decision-making, but to provide decision makers with the data that they need to achieve community-wide substance use prevention and treatment goals, including the increased delivery of high-quality, evidence-informed, services and the prevention of overdoses.
Eligibility Criteria
Inclusion Criteria: Sample 1: Local or Regional Decision Makers * At least 18 years old * Has decision-making authority within their professional role related to substance use service delivery, including leadership responsible for developing policy (e.g. executive directors) OR middle-managers (e.g., case managers, supervisor) and front-line workers responsible for service delivery decisions OR Responsible for developing local or state policy related to substance use/behavioral health and/or the criminal justice system OR Advises these decision makers (e.g., legislative staff, data analysts) These individuals will be drawn from organizations with the following perspectives: behavioral health, public health, health payer, first responders, health advocacy. Sample 2: State or Local Decision Makers * At least 18 years old * Has decision-making authority within their professional role related to substance use service delivery, including leadership responsible for developing policy (e.g. executive directors) OR middle-managers (e.g., case managers, supervisor) and front-line workers responsible for service delivery decisions OR Responsible for developing local or state policy related to substance use/behavioral health and/or the criminal justice system OR Advises these decision makers (e.g., legislative staff, data analysts) Exclusion Criteria: * None.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06852170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Substance Abuse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06852170 currently recruiting?
Yes, NCT06852170 is actively recruiting participants. Contact the research team at gcruden@chestnut.org for enrollment information.
Where is the NCT06852170 trial being conducted?
This trial is being conducted at Eugene, United States.
Who is sponsoring the NCT06852170 clinical trial?
NCT06852170 is sponsored by Chestnut Health Systems. The trial plans to enroll 341 participants.